NASDAQ: QUREUniqure Nv Stock
$44.00-0.09 (-0.2%)
Updated Sep 18, 2026
QURE Price
$44.00
Fair Value Price
-$8.53
Market Cap
$3.05B
52 Week Low
$8.73
52 Week High
$71.50
P/E
-10.97x
P/B
9.42x
P/S
163.41x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.67M
Earnings
-$252.21M
Gross Margin
92.5%
Operating Margin
-993.35%
Profit Margin
-1,350.7%
Debt to Equity
2.04
Operating Cash Flow
-$161M
Beta
1.3
Next Earnings
Nov 9, 2026
Ex-Dividend
N/A
Next Dividend
N/A
QURE Overview
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine QURE's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
QURE
Ranked#239 of 461
Ranked#239 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.60 | A | |
| $350.84 | A | |
| $42.02 | A |
Be the first to know about important QURE news, forecast changes, insider trades & much more!
QURE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how QURE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
QURE ($44.00) is overvalued by 615.67% relative to our estimate of its Fair Value price of -$8.53 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
QURE ($44.00) is not significantly undervalued (615.67%) relative to our estimate of its Fair Value price of -$8.53 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
QURE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more QURE due diligence checks available for Premium users.
Valuation
QURE fair value
Fair Value of QURE stock based on Discounted Cash Flow (DCF)
Price
$44.00
Fair Value
-$8.53
Undervalued by
615.67%
QURE ($44.00) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
QURE ($44.00) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
QURE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
QURE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-10.97x
Industry
9.29x
Market
44.48x
QURE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
9.42x
Industry
5.28x
QURE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
QURE's financial health
Profit margin
Revenue
$5.8M
Net Income
-$81.1M
Profit Margin
-1,387.8%
QURE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
QURE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$985.1M
Liabilities
$661.1M
Debt to equity
2.04
QURE's short-term assets ($834.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QURE's short-term assets ($834.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QURE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
QURE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$28.6M
Investing
$53.3M
Financing
$249.1M
QURE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
QURE vs Biotech Stocks
Uniqure Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.